EL
ELTP.US Elite Pharma Inc
- Market cap
- USD 345M
- P/E
- 8.0x
- P/B
- 2.52x
- ROE
- 22.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ELTP.US undervalued?
Graham numberELTP.US trades 5.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elite Pharma Inc fundamental analysis
No fundamental analysis for Elite Pharma Inc yet.
Elite Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elite Pharma Inc
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg…
Full company profileElite Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elite Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.64M | 7.46M | 7.57M | 18.0M | 25.4M | 32.3M | 34.2B | 56.6M | 84.0M | 149M | 129M |
| Gross Profit | 3.74M | 3.95M | 2.87M | 7.98M | 11.9M | 14.8M | 16.6B | 26.4M | 40.1M | 75.0M | 54.0M |
| Operating Income | -7.36M | -9.05M | -9.16M | -2.29M | 2.10M | 5.07M | 2.03B | 10.8M | 21.2M | 50.0M | 30.1M |
| EBITDA | -6.63M | -8.04M | -7.88M | -763K | 3.63M | 6.51M | 3.29B | 2.57M | 2.84M | 59.2M | 33.1M |
| Net Income | 3.81M | -3.67M | -9.28M | -2.24M | 5.09M | 8.90M | 4.41B | 20.1M | -4.31M | 44.9M | 23.6M |
| EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | 0.01 | 4.35 | 0.02 | 0.00 | 0.04 | 0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 34.3M | 30.9M | 24.4M | 25.0M | 26.2M | 35.1M | 40.9M | 83.7M | 96.4M | 138M | 140M |
| Total Liabilities | 8.65M | 12.4M | 13.0M | 14.3M | 10.0M | 9.93M | 11.9M | 26.1M | 42.9M | 39.4M | 34.8M |
| Shareholders' Equity | 25.7M | 18.5M | 11.4M | 10.7M | 16.2M | 25.2M | 29.0M | 57.6M | 53.5M | 98.9M | 105M |
| Cash & Short-term Investments | 10.6M | 7.18M | 2.28M | 1.13M | 3.19M | 8.54M | 7.83M | 7.11M | 11.3M | 29.8M | 38.9M |
| Total Debt | 2.65M | 3.99M | 3.98M | 4.03M | 2.38M | 2.78M | 3.89M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.88M | -4.81M | -6.79M | -1.79M | 3.19M | 6.51M | 3.34M | -3.24M | 7.46M | 23.7M | 40.3M |
| Capital Expenditure | 1.10M | 275K | 19.1K | 35.0K | 330K | 499K | 5.74M | 810K | 2.53M | 926K | 3.24M |
| Free Cash Flow | -8.99M | -5.08M | -6.81M | -1.83M | 2.86M | 6.01M | -2.40M | -4.04M | 4.93M | 22.8M | 37.0M |
| Ratios | |||||||||||
| ROE | 14.9% | -19.9% | -81.4% | -21.0% | 31.5% | 35.3% | 15,227.4% | 34.9% | -8.1% | 45.4% | 22.6% |
| ROA | 11.1% | -11.9% | -38.0% | -9.0% | 19.4% | 25.3% | 10,783.2% | 24.0% | -4.5% | 32.4% | 16.9% |
| Net Profit Margin | 39.5% | -49.2% | -122.6% | -12.5% | 20.0% | 27.6% | 12.9% | 35.5% | -5.1% | 30.1% | 18.3% |
| Debt to Equity | 0.10x | 0.22x | 0.35x | 0.38x | 0.15x | 0.11x | 0.13x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Elite Pharma Inc dividends
Elite Pharma Inc has not paid dividends in the last 9 fiscal years.
Who owns Elite Pharma Inc
- Insiders 22.40%
- Institutions 0.00%
- Public & others 77.60%
- Shares outstanding 1.08B
- Free float 836M
Elite Pharma Inc company profile
- Company name
- Elite Pharma Inc
- Ticker
- ELTP.US
- Exchange
- USA Stocks
- Listed since
- Jul 23, 1998
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 65
- Fiscal year end
- March
- Address
- 165 Ludlow Avenue, Northvale, NJ, United States, 07647
- Phone
- 201 750 2646
- Website
- elitepharma.com
About Elite Pharma Inc
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. It also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; Methotrexate Sodium 2.5mg tablets for the treatment of Antimetabolite under the Otrexup PF brand; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; Acetaminophen and Hydrocodone Bitartrate capsules for the treatment of pain under the Norco brand; Lisdexamfetamine Dimesylate to treat ADHD under the Vyvanse brand; Oxycodone Hydrochloride and Acetaminophen tablets to treat pain under the Percocet brand name; and Methadone Hydrochloride tablets for the treatment of pain under the Dolophine brand. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of allergy, bariatric, attention deficit, and infection. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
Elite Pharma Inc management
7- Mr. Nasrat HakimChairman, CEO & President · born 1961
- Mr. Carter J. Ward CPA, CSCPCFO, Secretary & Treasurer · born 1964
- Mr. Douglas PlasscheExecutive Vice President of Operations · born 1964
- Ms. Dianne WillVice President of Investor Relations & Corporate Affairs
- Dr. George Kenneth Smith J.D., M.B.A., Ph.D.Vice President of Legal
- Mr. Christopher C. DickHead of Development · born 1955
- Mr. Kirko KirkovChief Commercial Officer · born 1968